CREBBP and mantle cell lymphoma: Zhou et al. found that CREBBP/EP300 inhibitors inhibited RTKs and the downstream activation of MAPK/ERK signaling, thereby overcoming mantle cell lymphoma (MCL) cells’ resistance to idelalisib in vitro and in vivo [144].